Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
35,774 Shares in Ionis Pharmaceuticals, Inc. $IONS Purchased by Stanley Laman Group Ltd.
07:04am, Monday, 05'th Jan 2026
Stanley Laman Group Ltd. acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) in the undefined quarter, according to its most recent 13F filing with the Securities and Excha
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
11:16am, Monday, 22'nd Dec 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Assenagon Asset Management S.A. Boosts Stock Position in Ionis Pharmaceuticals, Inc. $IONS
03:27am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 1,669.0% during the undefined quarter, according to its most recent filing with the Securities and
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS
04:18am, Friday, 05'th Dec 2025
Capital Fund Management S.A. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 46.2% in the second quarter, according to the company in its most recent Form 13F filing with the SE
American Century Companies Inc. Raises Holdings in Ionis Pharmaceuticals, Inc. $IONS
03:18am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 304.9% during the undefined quarter, according to the company in its most recent filing with the SEC.
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
07:00am, Tuesday, 02'nd Dec 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganers
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
07:00am, Monday, 01'st Dec 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of “Moderate Buy” by Brokerages
01:38am, Saturday, 29'th Nov 2025
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-two research firms that are covering the stock, Marketbeat Ratings r
Tweedy Browne's Strategic Moves: Alphabet Inc. Sees a -1.43% Portfolio Impact
10:01am, Thursday, 20'th Nov 2025
Exploring Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing and Investment Adjustments Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 Transcript
10:08am, Tuesday, 18'th Nov 2025
Ionis Pharmaceuticals, Inc. ( IONS ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants A
Biogen Completes Acquisition of Alcyone Therapeutics
04:05pm, Friday, 14'th Nov 2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
07:00am, Friday, 14'th Nov 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript
12:41pm, Thursday, 13'th Nov 2025
Ionis Pharmaceuticals, Inc. ( IONS ) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L.
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
12:39am, Thursday, 13'th Nov 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the �
